Balanced news tone
News Sentiment
ALKS sentiment intelligence
Alkermes Plc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-4.8% over one week, +17.3% over four weeks, trend active, and materially above fair value.
Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS)
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 05:04
- Source
- simplywall.st
Alkermes to Report Second Quarter Financial Results on July 28, 2026
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 20:00
- Source
- Business Wire
Needham Maintains Alkermes(ALKS.US) With Buy Rating, Raises Target Price to $62
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 14 Jul 2026 09:48
- Source
- Moomoo
What's Going on With Alkermes Stock Monday? - Alkermes (NASDAQ:ALKS)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 15:06
- Source
- Benzinga
TD Cowen raises Alkermes stock price target to $57 on drug data By Investing.com
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 13 Jul 2026 15:03
- Source
- Investing.com South Africa
Alkermes Public's Alixorexton Demonstrates Durable Efficacy in Narcolepsy Patients
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 12:01
- Source
- MT Newswires
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 11:00
- Source
- Business Wire
Experimental narcolepsy pill from Alkermes keeps patients awake and alert for up to nine months
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 11:00
- Source
- Stock Titan
JPMorgan resumes Alkermes stock coverage with neutral rating By Investing.com
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 13 Jul 2026 08:52
- Source
- Investing.com Australia
Alkermes PLC (ALKS) Stock Down 3.4% but Still Overvalued -- GF S
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 21:56
- Source
- GuruFocus
Is Alkermes (ALKS) Fully Priced As Russell 2000 Index Inclusion Draws Fresh Attention?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 05:00
- Source
- simplywall.st
The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 07:00
- Source
- simplywall.st
Alkermes Insider Sold Shares Worth $463,621, According to a Recent SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 08:15
- Source
- MT Newswires
Alkermes (ALKS) Is Up 9.3% After Strong Alixorexton Phase 2 Data And Russell 2000 Addition - What's Changed
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 30 Jun 2026 14:07
- Source
- Simply Wall St.
Alkermes Stock 7-Day Winning Spree: Stock Climbs 25%
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 07:00
- Source
- Trefis
Alkermes Stock On Fire: Up 25% With 7-Day Winning Streak
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 07:00
- Source
- Trefis
Alkermes stock hits 52-week high at 45.76 USD
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Investing.com
Alkermes Plc (ALKS) Stock Analysis: Growth Potential With A 28.20% Revenue Surge
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 15 Jun 2026 07:00
- Source
- DirectorsTalk Interviews
Alkermes’ alixorexton receives orphan drug designations in US, EU
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Investing.com
Alkermes stock hits 52-week high at 44.58 USD
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Investing.com
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jun 2026 07:00
- Source
- Market source
Alkermes plc stock (IE00B56GVS15): 52-week high after Q1 beat
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Ad Hoc News
Alkermes (ALKS) finance VP exercises options and sells 16,217 shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Stock Titan
Alkermes stock hits 52-week high at $38.94
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 May 2026 07:00
- Source
- Investing.com
Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- Market source
Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- simplywall.st
Is It Time To Reassess Alkermes (ALKS) After Strong Recent Share Price Gains
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 09 May 2026 07:00
- Source
- simplywall.st
Alkermes (ALKS) Margin Compression Tests Bullish Earnings Growth Narratives Ahead Of Q1 2026
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- simplywall.st
Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company (ALKS)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- Seeking Alpha
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 May 2026 07:00
- Source
- Market source